- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11.25 | FluoGuide A/S Publishes Interim Report Q3 2025 | 245 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11.25 | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 297 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | Minutes from Extraordinary General Meeting in FluoGuide A/S | 223 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen | |
| 24.11.25 | Invitation to FluoGuide A/S Webcast on 27 November 2025 | 246 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy | 295 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Convenes an Extraordinary General Meeting | 253 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees | 283 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, members... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Completes Directed Share Issue of SEK 104 Million | 308 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million | 269 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 28.10.25 | FluoGuide A/S: FluoGuide in Advanced Negotiations on Collaboration Agreement with a World Leading Medical Technology Company | 178 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / October 28, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company specializing in precision cancer surgery, announces to be in advanced... ► Artikel lesen | |
| 16.09.25 | FluoGuide A/S: FluoGuide Receives Positive FDA Feedback on FG001 in High-Grade Glioma | 262 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / September 16, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") received positive feedback and alignment with the FDA at a pre-IND consultation on its U.S. clinical... ► Artikel lesen | |
| 28.08.25 | FluoGuide A/S Publishes Interim Report H1 2025 | 220 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 28, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 28 August 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period... ► Artikel lesen | |
| 22.08.25 | Invitation to FluoGuide A/S Webcast on 28 August 2025 | 280 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 22, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q2 2025 on Thursday 28 August 2025.The following event will take place later... ► Artikel lesen | |
| 21.07.25 | FluoGuide A/S: FluoGuide Enters Collaboration with Global MedTech Company Olympus | 528 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 21, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with... ► Artikel lesen | |
| 03.07.25 | FluoGuide A/S: Update on 2025 Outlook and Company progress | 317 | GlobeNewswire (Europe) | Copenhagen, Denmark, 3 July 2025 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an update on the 2025 Outlook... ► Artikel lesen | |
| 10.06.25 | FluoGuide A/S: FG001 clinical data in High-Grade Glioma is now published in Neurosurgery | 623 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision... ► Artikel lesen | |
| 28.05.25 | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - March 2025 - On track - first patients enrolled in CT-005 | 233 | GlobeNewswire (Europe) | Copenhagen, Denmark, 28 May 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2025. The Q1 report is available as an attached document... ► Artikel lesen | |
| 15.04.25 | FluoGuide A/S: FluoGuide includes first patient in phase II trial of FG001 for head and neck cancer | 238 | GlobeNewswire (Europe) | Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase... ► Artikel lesen | |
| 27.03.25 | Minutes from Annual General Meeting in FluoGuide A/S | 356 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 27, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 12.03.25 | Notice of Annual General Meeting in FluoGuide A/S | 411 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 39,010 | +3,94 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| GENEDX | 119,24 | -11,92 % | GeneDx Holdings Corp. - 8-K, Current Report | ||
| FRESENIUS | 50,72 | 0,00 % | dpa-AFX-Überblick: UNTERNEHMEN vom 09.01.2026 - 15.15 Uhr | ROUNDUP: Teamviewer erreicht Umsatzziel für 2025 - Aktie mit Erholungsversuch GÖPPINGEN - Der Softwareanbieter Teamviewer hat 2025 sein im Herbst gesenktes Umsatzziel knapp erreicht. Basierend auf... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | 0,00 % | Fresenius Medical Care startet zweite Tranche des Aktienrückkaufs | Die Fresenius Medical Care AG setzt ihr im Juni 2025 angekündigtes Aktienrückkaufprogramm beschleunigt fort. Nach dem vorzeitigen Abschluss der ersten Tranche am 29. Dezember 2025 startet nun die zweite... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,970 | 0,00 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Siemens Healthineers auf "Hold" mit einem Kursziel von 46 Euro belassen. Er rechne damit, dass der Start in das neue Geschäftsjahr... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,280 | 0,00 % | Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026 | Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year... ► Artikel lesen | |
| PROGYNY | 28,420 | +5,30 % | Progyny, Inc. - 8-K, Current Report | ||
| OUTSET MEDICAL | 5,570 | 0,00 % | Outset Medical, Inc.: Outset Medical Reports Unaudited Fourth Quarter and 2025 Results | SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis... ► Artikel lesen | |
| HEARTFLOW | 31,790 | -4,07 % | Heartflow, Inc. - 8-K, Current Report | ||
| ADAPTHEALTH | 10,600 | +1,05 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| BETA BIONICS | 17,620 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics | IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 41,180 | 0,00 % | EQS-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Carl Zeiss Meditec AG
Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the... ► Artikel lesen | |
| GERRESHEIMER | 27,860 | 0,00 % | Bechtle, Gerresheimer, HelloFresh, Kontron, Lanxess, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| RXSIGHT | 10,090 | +14,14 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 31,340 | -4,54 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
Das Unternehmen FLUOGUIDE A/S kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.